Angiotensin II 5-valine

Cas No.:	58-49-1
Chemical Name:	Angiotensin II, 5-L-valine-
Synonyms:	Valine angiotensin II;5-L-Valine angiotensin II
SMILES:	NC(NCCC[C@H](NC([C@@H](N)CC(O)=O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=C(O)C=C1)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CN=CN1)C(N1[C@H](C(N[C@@H](CC2=CC=CC=C2)C(O)=O)=O)CCC1)=O)=O)=O)=O)=O)=N.CC(O)=O
Formula:	C49H69N13O12
M.Wt:	1032.152
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	Angiotensin II 5-valine is an agonist of angiotensin receptor.
Target:	Angiotensin receptor[1].
In Vitro:	By day 12, systolic blood pressure (SBP) increases significantly in Angiotensin II 5-valine infused rats (197±7 mm Hg). As shown, the development of hypertension in ANG II infused rats is prevented by losartan treatment. Blood and kidney samples are harvested, subjected to HPLC to separate Angiotensin II 5-valine (exogenous) from Ile5-ANG II (endogenous) and the fractions are measured by radioimmunoassay. In the Angiotensin II 5-valine infused rats treated with losartan, total plasma ANG II levels are elevated to a greater extent than in rats not treated with losartan (289±20 v 119±14 fmol/mL). However, losartan markedly decrease by 88% the enhancement of intrarenal Val5-ANG II content that occurred in the rats infused with Val5-ANG II alone[1].
Animal Administration:	Rats[1] Male Sprague Dawley rats are uninephrectomized and divided into three groups: control (n=6), Angiotensin II 5-valine (exogenous form) infused (n=8), and Angiotensin II 5-valine infused rats treat with losartan (n=8). Angiotensin II 5-valine, which has the same biological and immunoreactive properties as endogenous ANG II, was infused at 40 ng/min via an osmotic minipump implant subcutaneously[1].
References:	[1]. Zou LX et al. Renal uptake of circulating angiotensin II in Val5-angiotensin II infused rats is mediated by AT1 receptor. Am J Hypertens. 1998 May;11(5):570-8.